A systematic review and network meta-analysis of the efficacy and safety of third-line and over third-line therapy after imatinib and TKI resistance in advanced gastrointestinal stromal tumor

被引:2
|
作者
Xiao, Xianhao [1 ]
Yuan, Weiye [1 ]
Wang, Chong [1 ]
Song, He [1 ]
机构
[1] First Hosp China Med Univ, Shenyang, Liaoning, Peoples R China
关键词
gastrointestinal stromal tumor; precise targeted therapy; refractory GIST; network meta-analysis; systematic review; PHASE-III; KINASE INHIBITOR; TYROSINE KINASE; SUPPORTIVE CARE; OPEN-LABEL; MULTICENTER; SUNITINIB; KIT; MESYLATE; TRIAL;
D O I
10.3389/fphar.2022.978885
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tyrosine kinase inhibitors (TKIs) have greatly improved the prognosis of unresectable and metastatic gastrointestinal stromal tumors (GISTs) in the last two decades. Imatinib and sunitinib are recommended as first-line and second-line therapies, respectively. However, there is a lack of precision therapy for refractory GISTs regarding therapy after imatinib and sunitinib. We comprehensively searched electronic databases, including PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials, from inception to October 2022. Randomized controlled trials featuring comparisons with third-line or over third-line therapies against GISTs were eligible. The primary outcome was progression-free survival (PFS). All network calculations were performed using random effect models, and the ranking of regimens were numerically based on the surface under the cumulative ranking (SUCRA) statistics. A total of seven studies were eligible for inclusion in this network meta-analysis. After analysis, ripretinib was ranked at the top in progression-free survival (PFS), overall survival (OS), and disease control rate (DCR) (SUCRA statistics: 83.1%, 82.5%, and 86.5%, respectively), whereas nilotinib and pimitespib presented better tolerability (SUCRA statistics: 64.9% and 63.8%, respectively). We found that regorafenib seemed more reliable for clinical administration, and ripretinib showed good effectiveness for the over third-line therapy. Precise targeted therapy is a critical direction for the future treatment of GIST, and more high-quality studies of new agents are expected.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis
    Zhang, Chan
    Xiang, Yaoxian
    Wang, Jing
    Yan, Dong
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Comparison of Efficacy and Safety of Third-Line Treatments for Advanced Gastric Cancer: A Systematic Review With Bayesian Network Meta-Analysis
    Huang, Miao
    Li, Jisheng
    Yu, Xuejun
    Xu, Qian
    Zhang, Xue
    Dai, Xin
    Li, Song
    Sheng, Lei
    Huang, Kai
    Liu, Lian
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Third-line chemotherapy in advanced gastric cancer A systematic review and meta-analysis
    Zheng, Yu
    Zhu, Xu-Qing
    Ren, Xiao-Gang
    [J]. MEDICINE, 2017, 96 (24)
  • [4] Comparison of the efficacy and safety of third-line treatments for metastatic colorectal cancer: a systematic review and network meta-analysis
    Gao, Loulu
    Tang, Lin
    Hu, Zixuan
    Peng, Jieqiong
    Li, Xiaoqian
    Liu, Bo
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [5] Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis
    Park, Sejung
    Nam, Chung Mo
    Kim, Seul-Gi
    Mun, Ji Eun
    Rha, Sun Young
    Chung, Hyun Cheol
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 144 : 49 - 60
  • [6] Efficacy and safety of regorafenib as third-line therapy in metastatic colorectal cancer: An indirect meta-analysis
    Wu, Yinying
    Fan, Yangwei
    Dong, Dan Feng
    Dong, Xuyuan
    Hu, Yuan
    Shi, Yu
    Jing, Jiayu
    Li, En Xiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] A SYSTEMATIC REVIEW AND EXPLORATORY NETWORK META-ANALYSIS OF THIRD-LINE TREATMENTS FOR METASTATIC COLORECTAL CANCER
    Walter, T.
    Hawkins, N. S.
    Pollock, R.
    Colaone, F.
    Shergill, S.
    Ross, P. J.
    [J]. VALUE IN HEALTH, 2020, 23 : S30 - S30
  • [8] Phase 2 Study of Nilotinib as Third-Line Therapy for Patients With Gastrointestinal Stromal Tumor
    Sawaki, Akira
    Nishida, Toshirou
    Doi, Toshihiko
    Yamada, Yasuhide
    Komatsu, Yoshito
    Kanda, Tatsuo
    Kakeji, Yoshihiro
    Onozawa, Yusuke
    Yamasaki, Makoto
    Ohtsu, Atsushi
    [J]. CANCER, 2011, 117 (20) : 4633 - 4641
  • [9] Comparison of the efficacy of third-line treatments for metastatic colorectal cancer: A network meta-analysis
    Taieb, J.
    Yahiaoui, S.
    Choucair, E.
    Yao, W.
    Hauch, O.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S29 - S29
  • [10] Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis
    Feuerstein, Joseph D.
    Akbari, Mona
    Tapper, Elliot B.
    Cheifetz, Adam S.
    [J]. ANNALS OF GASTROENTEROLOGY, 2016, 29 (03): : 341 - 347